MARKET

INNMF

INNMF

Amplia Therapeutics Ltd
OTCMQB
0.100
NaN%
Closed 09:30 09/15 EDT
OPEN
--
PREV CLOSE
0.100
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.256
52 WEEK LOW
0.070
MARKET CAP
51.33M
P/E (TTM)
-8.8496
1D
5D
1M
3M
1Y
5Y
1D
Amplia Wins Strong Shareholder Backing for AGM Resolutions and Capital Flexibility
TipRanks · 08/28 02:27
Amplia Therapeutics Highlights Strong Pancreatic Cancer Data in AGM CEO Presentation
TipRanks · 08/28 00:10
Amplia Showcases Lead FAK Inhibitor as Pancreatic Cancer Data Strengthen Oncology Push
TipRanks · 08/06 00:28
Bell Potter Reaffirms Their Buy Rating on Amplia Therapeutics (INNMF)
TipRanks · 08/05 00:05
Scientific Paper Detailing Preclinical Studies of Narmafotinib in Pancreatic Cancer Now Online
Barchart · 07/31 07:45
Amplia bolsters narmafotinib case with comprehensive pancreatic cancer data
TipRanks · 07/30 23:26
Amplia advances FAK inhibitor program with new trials, patent gains and board refresh
TipRanks · 07/28 23:23
Amplia Therapeutics Issues New Employee Incentive Options
TipRanks · 07/15 08:38
More
About INNMF
Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development company. The Company is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. Its pipeline includes narmafotinib (AMP945) and AMP886. Its lead drug candidate, narmafotinib, is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The Company’s second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue.

Webull offers Amplia Therapeutics Ltd stock information, including OTCMQB: INNMF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INNMF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INNMF stock methods without spending real money on the virtual paper trading platform.